FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience.
Jennifer Jane GileFang-Shu OuAmit MahipalJoseph J LarsonKabir ModyZhaohui JinJoleen M HubbardThorvardur R HalfdanarsonSteven R AlbertsAminah JatoiRobert R McWilliamsWen Wee MaSumera IlyasRory SmootLewis Rowland RobertsGregory GoresMitesh J BoradTanios S Bekaii-SaabNguyen H TranPublished in: JCO precision oncology (2021)
FGFRi are well tolerated with clinical efficacy. With the recent approval of FGFRi by the US Food and Drug Administration and ongoing clinical trials for new FGFRi, understanding outcomes and toxicity associated with these medications is important for precision oncology.